BioSpace News Archive

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

These life sciences companies are falling into some cold, hard investment cash.

The news sparked a mini-surge in shares of I-Mab, which were up 7.8% in pre-market U.S trading on September 28.

Horizon was adding five new development programs for daxdilimab and dazodalibep. This brings the company’s pipeline to 27 development programs.

EDIT-101 targets a disease-causing mutation in the CEP290 gene that causes degeneration in ocular photoreceptor cells, which are critical for normal vision.

Galderma announced the presentation of new phase 2 data supporting the efficacy of its investigational monoclonal antibody, nemolizumab, at the virtual 30th EADV congress, taking place between 28 September and 2 October 2021.

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, presented three-year results from the TANGO study at IDWeek 2021, being held virtually 29 September - 3 October.

The demand within the global healthcare provider network management market is set to increase at a sturdy rate in the times to follow.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per the insights by Fact.MR, the global dental lasers market is registered year on year growth at 9.0% in 2019.

Celldex Therapeutics, Inc. announced positive data on measurements of symptom control and quality of life from the Company’s ongoing, open label Phase 1b clinical trial of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism, the two most common forms of chronic inducible urticaria.